Journal of Clinical Medicine

MDPI

Supplementary Table 1. Pilot study cohort baseline clinical characteristics.

	Overall N = 19	**Controls N = 10**	**Cases N = 9**	***p***
Demographic				
Male sex, n (%)	6 (31.6)	4 (40.0)	2 (22.2)	0.405
Age (years), median (IQR)	80 (74-83)	80 (74-84)	80 (74-85)	1.000
Comorbidities, n (%)				
Hypertension	19 (100)	10 (100)	9 (100)	1.000
Diabetes mellitus	4 (21.1)	2 (20.0)	2 (22.2)	0.906
Heart failure	6 (31.6)	3 (30.0)	3 (33.3)	0.876
History of stroke/TIA/thromboembolism	5 (26.3)	3 (30.0)	2 (22.2)	0.701
Renal impairment	2 (10.5)	2 (20.0)	0 (0.0)	0.156
Coronary artery disease	1 (5.3)	0 (0.0)	1 (11.1)	0.279
Hypercholesterolemia	1 (5.3)	1 (10.0)	0 (0.0)	0.330
Current smoking habit	1 (5.3)	1 (10.0)	0 (0.0)	0.330
Current alcohol consumption	1 (5.3)	1 (10.0)	0 (0.0)	0.330
History of previous bleeding	1 (5.3)	0 (0.0)	1 (11.1)	0.279
Concomitant treatment, n (%)				
Amiodarone	1 (5.3)	0 (0.0)	1 (11.1)	0.279
Digoxin	4 (21.1)	2 (20.0)	2 (22.2)	0.906
Calcium antagonist	1 (5.3)	1 (10.0)	0 (0.0)	0.330
Beta-blockers	8 (42.1)	3 (30.0)	5 (55.6)	0.260
Statins	2 (10.5)	1 (10.0)	1 (11.1)	0.937
Diuretics	10 (52.6)	2 (20.0)	8 (88.9)	0.003
Antiplatelet therapy	3 (15.8)	2 (20.0)	1 (11.1)	0.596
ACE inhibitors / ARBs	11 (57.9)	4 (40.0)	7 (77.8)	0.096
TTR at 6 months of entry, n (%)	83 (66-100)	83 (78-100)	75 (56-100)	0.549
CHA_2DS_2-VASc score, median (IQR)	5.0 (3.0-6.0)	4.5 (3.0-6.0)	5.0 (3.5-5.5)	0.968
HAS-BLED score, median (IQR)	2.0 (2.0-3.0)	2.5 (2.0-4.0)	2.0 (2.0-3.0)	0.720

ACE inhibitors = angiotensin-converting-enzyme inhibitors; ARBs = angiotensin II receptor blockers; IQR = interquartile range; TIA = transient ischemic attack; TTR = time in therapeutic range.